Epistem Announce Agency Agreement with Veritas Japan

Epistem Plc has announced that its Contract Research Services division has entered into an agreement with the Veritas Corporation toexclusively market and distribute Epistem’s scientific research services in Japan.

Located in Manchester England, Epistem’s contract research division provides specialised preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammatory bowel disease, wound healing and skincare. Epistem have an established customer base in Western Europe and the US and the Veritas agreement will provide Epistem with a sales and marketing presence in Japan and the opportunity to extend its research services, and respond rapidly to market demand.

Epistem’s CEO Matthew Walls commented: “We are delighted to be working with Veritas. They have a strong scientific sales team and established distribution network. The Japanese drug development market provides us with an important opportunity for growth and the agreement with Veritas will allow us to develop closer links with existing Japanese customers.”

Sinsaku Lida, Veritas CEO, said: ”It is our great pleasure to work with Epistem. Epistem’s Contract Research Division has a strong preclinical and scientific research service capability which will benefit Japanese pharmaceutical and personal care companies. Veritas’ sales network has the scientific experience necessary to introduce Epistem’s high quality services to potential Japanese customers and will make for more efficient marketing and easier access for Japanese customers to Epistem.“